Chronic Hyperkalemia Management Therapeutics
1. Lokelma patent expiration
Treatment: Treatment of hyperkalemia in adults
LOKELMA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9592253 | ASTRAZENECA | Extended use zirconium silicate compositions and methods of use thereof |
Oct, 2035
(9 years from now) | |
| US10300087 | ASTRAZENECA | Extended use zirconium silicate compositions and methods of use thereof |
Oct, 2035
(9 years from now) | |
| US9913860 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(7 years from now) | |
| US10413569 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(6 years from now) | |
| US10695365 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(7 years from now) | |
| US8877255 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(7 years from now) | |
| US11406662 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(6 years from now) | |
| US8802152 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Apr, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6332985 | ASTRAZENECA | Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions |
Mar, 2019
(6 years ago) | |
| US9844567 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(6 years from now) | |
| US9861658 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(6 years from now) | |
| US11738044 | ASTRAZENECA | Extended use zirconium silicate compositions and methods of use thereof |
Oct, 2035
(9 years from now) | |
| US8808750 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(6 years from now) | |
| US10398730 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(6 years from now) | |
| US10335432 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-261) | Apr 24, 2023 |
| New Chemical Entity Exclusivity(NCE) | May 18, 2023 |
Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient
NCE-1 date: 18 May, 2022
Market Authorisation Date: 18 May, 2018
Dosage: FOR SUSPENSION
How can I launch a generic of LOKELMA before it's drug patent expiration?
More Information on Dosage
LOKELMA family patents
2. Veltassa patent expiration
Treatment: Treatment of hyperkalemia
VELTASSA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8337824 | VIFOR PHARMA | Linear polyol stabilized polyfluoroacrylate compositions |
May, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778324 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 9 months ago) | |
| US7556799 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Feb, 2025
(10 months ago) | |
| US8889115 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 9 months ago) | |
| US8216560 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2027
(1 year, 2 months from now) | |
| US9492476 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(7 years from now) | |
| US8287847 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 9 months ago) | |
| US8475780 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 9 months ago) | |
| US10485821 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 9 months ago) | |
| US9925212 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(7 years from now) | |
| US11123363 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(7 years from now) | |
| US8147873 | VIFOR PHARMA | Methods and compositions for treatment of ion imbalances |
Jun, 2028
(2 years from now) | |
| US8282913 | VIFOR PHARMA | Ion binding polymers and uses thereof |
May, 2027
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2020 |
| New Patient Population(NPP) | Oct 02, 2026 |
| New Strength(NS) | Oct 02, 2026 |
Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient
NCE-1 date: 22 October, 2019
Market Authorisation Date: 02 October, 2023
Dosage: POWDER
How can I launch a generic of VELTASSA before it's drug patent expiration?
More Information on Dosage
VELTASSA family patents